STOCK TITAN

TG Therapeutics to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
TG Therapeutics, Inc. (TGTX) announces CEO's participation in the 6th Annual Evercore ISI HealthCONx Conference on November 29, 2023. The fireside chat will be available via live webcast on the company's website.
Positive
  • None.
Negative
  • None.

Fireside chat scheduled for Wednesday, November 29, 2023, at 2:10 PM ET

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 6th Annual Evercore ISI HealthCONx Conference, being held at the Kimpton EPIC Hotel, in Miami, Florida on November 28 - 30, 2023. The fireside chat is scheduled to take place on Wednesday, November 29, 2023, at 2:10 PM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received approval from the U.S. FDA for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as European Commission (EC) approval for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6


FAQ

What is the date and time of the fireside chat at the 6th Annual Evercore ISI HealthCONx Conference for TG Therapeutics, Inc. (TGTX)?

The fireside chat is scheduled for Wednesday, November 29, 2023, at 2:10 PM ET.

Where will the fireside chat take place for TG Therapeutics, Inc. (TGTX)?

The fireside chat will be held at the Kimpton EPIC Hotel in Miami, Florida.

How can I access the live webcast of the fireside chat for TG Therapeutics, Inc. (TGTX)?

The live webcast will be available on the Events page of the company’s website at http://ir.tgtherapeutics.com/events.

TG Therapeutics, Inc.

NASDAQ:TGTX

TGTX Rankings

TGTX Latest News

TGTX Stock Data

2.55B
134.88M
9.08%
59.26%
22.25%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About TGTX

tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".